Main considerable factors for correct laboratory test interpretation under DOA treatment

Thrombosis Journal

Volumn 11, Issue 1, 2013, Pages

  Mani, Helen ^a   Lindhoff Last, Edelgard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; APIXABAN; DABIGATRAN; FIBRINOGEN; RECOMBINANT THROMBOPLASTIN; RIVAROXABAN; THROMBOPLASTIN;

ANALYTIC METHOD; ANTICOAGULANT THERAPY; ANTICOAGULATION; ASSAY; CEREBROVASCULAR ACCIDENT; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; FIBRINOGEN BLOOD LEVEL; HUMAN; LABORATORY TEST; PROTEIN DETERMINATION; REVIEW;

EID: 84886736407     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-11-22     Document Type: Review

References (16)

1. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141(2 Suppl):e44S-88S. 3278051, 22315269.
2. Samama MM, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012, 130(Suppl 1):S88-89.
3. Lindhoff-Last E, Samama MM, Ortel TL, et al. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010, 32(6):673-69. 10.1097/FTD.0b013e3181f2f264, 20844464.
4. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007, 98:155-162.
5. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103(4):815-825. 10.1160/TH09-03-0176, 20135059.
6. Lindahl TL Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011, 105(2):371-378.
7. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011, 106(1):156-164. 10.1160/TH10-10-0667, 21655672.
8. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012, 107(5):985-997. 10.1160/TH11-11-0804, 22438031.
9. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103(6):1116-1127. 10.1160/TH09-11-0758, 20352166.
10. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013, 109(1):127-136.
11. Douxfils J, Mullier F, Loosen C, et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012, 130(6):956-966. 10.1016/j.thromres.2012.09.004, 23006523.
12. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011, 9(1):133-139. 10.1111/j.1538-7836.2010.04098.x, 20946166.
13. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011, 127(5):457-465. 10.1016/j.thromres.2011.01.001, 21277622.
14. Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013, 110(2):283-294. 10.1160/TH12-12-0898, 23765180.
15. Baglin T, Keeling D, Kitchen S. British Committee for Standards in Haematology. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012, 159(4):427-429. 10.1111/bjh.12052, 22970737.
16. Herth N, Mani H, Wenger F, et al. Dabigatran influences ex-vivo global coagulation assays in dependence of time of drug intake. Haemostaseologie 2011, A89(1):P17.5.